The average price target of $28.33 for Corcept Therapeutics, as determined by 6 analysts, implies an upside from the current price of $24.16. This suggests that the stock is likely to go up in the short term, as the analysts' opinions are generally based on thorough research and analysis of the company's financials and market position. The 7.11% decrease in the average price target from the previous target of $30.50 may indicate a slightly lower growth expectation, but the overall sentiment remains positive.